SS 29 - Bio 4: Immunotherapy and Immune Response

Moderator(s)

• 

  Kristina Young, MD, PhD

  The Oregon Clinic Radiation Oncology
  Portland, OR
• 

  Zachary Buchwald, MD, PhD

  Emory University
  Atlanta, GA

Presentations:

• 12:45 PM – 12:55 PM ET

  The Eclipse-Radiotherapy Combined with ICI Orchestrates CD8+ T Cell- and NK Cell-Dependent Anti-Tumor Efficacy against Bulky Tumors
  

  Presenter: Ren Luo, MD, PhD – West China Hospital of Sichuan University
• 12:55 PM – 1:05 PM ET

  Tumor Immunity Following Radiopharmaceutical + Checkpoint Blockade Varies with Treatment Sequence, Radioisotope and Tumor Immunogenicity
  

  Presenter: Caroline Kerr, PhD – University of Wisconsin-Madison
• 1:05 PM – 1:15 PM ET

  Combining Proton Radiation Therapy and Mesothelin-Targeting Chimeric Antigen Receptor T-cell Therapy to Improve Outcomes in Pancreatic Cancer
  

  Presenter: Uri Amit, MD, PhD, MPH – Tel Aviv Sourasky Medical Center- Ichilov Hospital
• 1:15 PM – 1:25 PM ET

  A Microbial-Inspired Antibody-Drug Conjugate Unleashes Macrophage Functionalities for Cancer Immunotherapy
  

  Presenter: Benjamin Schrank, MD, PhD – MD Anderson Cancer Center
• 1:25 PM – 1:35 PM ET

  Tilting Immunometabolic Balance of Tumor Microenvironment by Targeting ENO1 in KRAS-Mutated Colorectal and Pancreatic Cancers
  

  Presenter: K. S. Clifford Chao, MD – China Medical University Hospital
• 1:35 PM – 1:45 PM ET

  The Role of RIPK1 in Mediating Enhanced Immune Responses Following Radiotherapy
  

  Presenter: Feifei Teng, MD, PhD – Shandong Anti-Cancer Association
• 1:45 PM – 1:55 PM ET

  Radiation-Induced TREM2-Expression on Tumor-Associated Macrophages Is a Target for Modulation of Immune Responses in Prostate Cancer
  

  Presenter: Janny Villa-Pulgarin, PhD – Weill Cornell Medical College